Technology Wanted

Seeking technologies for Vascular Wall/Metabolic Syndrome


As a fortune 500 multinational corporation operating in the healthcare sector, we are looking for certain new technologies to license or acquire. If you have technologies in these areas, we welcome you to get in touch via Tynax. We have the sales channels to effectively bring new healthcare products to market.

We are keenly aware of and continuously review discoveries and developments across the entire drug discovery and development community. To achieve this, our Review and Licensing Committees, each target a specific therapeutic area or technology. This means that we provide a formal review and response for every viable opportunity.

Areas of Interest:

- Vasular wall agent or target with mechanistic validation; these include

> Vascular inflammation agent or target

> A drug target that favorably affects vascular wall elements

- Acute therapy to lower vascular inflammation in high-risk patients (biologic or small molecule)

- Metabolic syndrome target with strong or predicted atherosclerosis

> Must treat at least two components of metabolic syndrome and be registerable on at least one; lack of detrimental effects on weight and/or insulin sensitivity a plus.


- Animal models of

> Two or more components of metabolic syndrome

> Plaque vulnerability

- Imaging methods that read out plaque composition or vulnerability

- Circulating biomarkers of plaque burden or vulnerability

- Alliances/consortia around vulnerable/high-risk plaque

Not interested in:

- Acute treatment for MI

- Post-MI therapeutics for myocardial preservation or perfusion-reperfusion injury

Patents and Intellectual Property

We will only consider technology covered by a patent.